Black Diamond Therapeutics (NASDAQ:BDTX) Posts Earnings Results, Beats Expectations By $0.03 EPS

Black Diamond Therapeutics (NASDAQ:BDTX) issued its earnings results on Thursday. The company reported ($0.28) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.31) by $0.03, Zacks reports.

Black Diamond Therapeutics Stock Performance

Shares of BDTX traded up $0.04 during trading hours on Thursday, hitting $1.90. The stock had a trading volume of 196,540 shares, compared to its average volume of 811,365. The firm has a 50-day moving average price of $2.25 and a 200 day moving average price of $3.24. Black Diamond Therapeutics has a fifty-two week low of $1.77 and a fifty-two week high of $7.66. The firm has a market capitalization of $107.51 million, a price-to-earnings ratio of -1.43 and a beta of 2.52.

Wall Street Analyst Weigh In

Separately, HC Wainwright reaffirmed a “buy” rating and set a $11.00 price target on shares of Black Diamond Therapeutics in a research report on Wednesday, November 6th.

Black Diamond Therapeutics Company Profile

Black Diamond Therapeutics, Inc, a clinical-stage oncology medicine company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as phase 1 clinical trial to treat glioblastoma.